| Working Paper |
File Downloads |
Abstract Views |
| Last month |
3 months |
12 months |
Total |
Last month |
3 months |
12 months |
Total |
| Bilateral monopolies and location choice |
0 |
0 |
0 |
19 |
0 |
1 |
5 |
78 |
| Can Competition Reduce Quality? |
0 |
0 |
1 |
48 |
0 |
0 |
1 |
292 |
| Can competition reduce quality? |
0 |
0 |
0 |
38 |
0 |
1 |
1 |
81 |
| Can competition reduce quality? |
0 |
0 |
0 |
123 |
0 |
1 |
2 |
193 |
| Can competition reduce quality? |
0 |
0 |
1 |
109 |
1 |
3 |
4 |
307 |
| Capital Taxation and Imperfect Competition: ACE vs. CBIT |
0 |
0 |
0 |
8 |
0 |
0 |
1 |
46 |
| Capital Taxation and Imperfect Competition: ACE vs. CBIT |
0 |
0 |
0 |
16 |
0 |
0 |
3 |
65 |
| Capital Taxation and Imperfect Competition: ACE vs. CBIT |
0 |
0 |
0 |
12 |
0 |
1 |
1 |
56 |
| Capital Taxation and Imperfect Competition: ACE vs. CBIT |
0 |
0 |
0 |
17 |
0 |
0 |
1 |
98 |
| Capital taxation and imperfect competition: ACE vs. CBIT |
0 |
0 |
0 |
18 |
0 |
0 |
0 |
49 |
| Competing with precision: incentives for developing predictive biomarker tests |
0 |
0 |
0 |
14 |
0 |
1 |
1 |
15 |
| Competing with precision: incentives for developing predictive biomarker tests |
0 |
0 |
0 |
27 |
0 |
0 |
0 |
10 |
| Competition and Physician Behaviour: Does the Competitive Environment Affect the Propensity to Issue Sickness Certificates? |
0 |
0 |
0 |
11 |
0 |
0 |
1 |
42 |
| Competition and Quality in Regulated Markets with Sluggish Demand |
0 |
0 |
0 |
45 |
2 |
2 |
3 |
208 |
| Competition and Quality in Regulated Markets: a Differential-Game Approach |
0 |
0 |
0 |
82 |
0 |
1 |
2 |
384 |
| Competition and Waiting Times in Hospital Markets |
0 |
0 |
0 |
108 |
0 |
3 |
4 |
412 |
| Competition and Waiting Times in Hospital Markets |
0 |
0 |
0 |
84 |
0 |
2 |
4 |
422 |
| Competition and Waiting Times in Hospital Markets |
0 |
0 |
0 |
143 |
0 |
1 |
4 |
579 |
| Competition and physician behaviour: Does the competitive environment the propensity to issue sickness certificates? |
0 |
0 |
0 |
70 |
0 |
0 |
0 |
77 |
| Competition and quality in regulated markets with sluggish demand |
0 |
0 |
0 |
44 |
0 |
1 |
2 |
181 |
| Competition and quality in regulated markets: a differential-game approach |
0 |
0 |
0 |
88 |
0 |
0 |
1 |
244 |
| Competition and quality in regulated markets: a differential-game approach |
0 |
1 |
1 |
150 |
0 |
2 |
5 |
491 |
| Competition matters: uniform vs. indication-based pricing of pharmaceuticals |
0 |
0 |
2 |
2 |
0 |
0 |
9 |
9 |
| Competition matters: uniform vs. indication-based pricing of pharmaceuticals |
0 |
0 |
15 |
15 |
4 |
8 |
32 |
32 |
| Competition, quality and integrated health care |
0 |
0 |
1 |
67 |
0 |
0 |
2 |
76 |
| Diffusion of Pharmaceuticals: Cross-Country Evidence of Anti-TNF drugs |
0 |
0 |
0 |
28 |
0 |
0 |
0 |
96 |
| Direct to Consumer Advertising in Pharmaceutical Markets |
0 |
0 |
0 |
569 |
0 |
4 |
5 |
2,587 |
| Direct-to-Consumer Advertising in Pharmaceutical Markets |
0 |
0 |
0 |
408 |
0 |
1 |
2 |
1,831 |
| Direct-to-Consumer Advertising in Pharmaceutical Markets |
0 |
0 |
0 |
16 |
0 |
1 |
6 |
99 |
| Do Treatment Decisions Depend on Physicians` Financial Incentives? |
0 |
0 |
0 |
36 |
2 |
2 |
2 |
52 |
| Do Treatment Decisions Depend on Physicians’ Financial Incentives? |
0 |
0 |
0 |
10 |
1 |
2 |
4 |
68 |
| Does Reference Pricing Drive Out Generic Competition in Pharmaceutical Markets? Evidence from a Policy Reform |
0 |
0 |
0 |
72 |
0 |
0 |
2 |
152 |
| Does Reference Pricing Drive Out Generic Competition in Pharmaceutical Markets? Evidence from a Policy Reform |
0 |
0 |
0 |
22 |
0 |
0 |
2 |
14 |
| Does Reference Pricing Drive Out Generic Competition in Pharmaceutical Markets? Evidence from a Policy Reform |
0 |
0 |
0 |
18 |
0 |
1 |
1 |
86 |
| Gatekeeping In Health Care |
0 |
0 |
0 |
148 |
1 |
1 |
3 |
606 |
| Gatekeeping in Health Care |
0 |
0 |
0 |
252 |
3 |
3 |
5 |
1,814 |
| Gatekeeping in health care |
0 |
0 |
0 |
7 |
0 |
0 |
1 |
104 |
| Horizontal Mergers and Product Quality |
0 |
0 |
0 |
28 |
0 |
0 |
0 |
61 |
| Horizontal Mergers and Product Quality |
0 |
0 |
0 |
35 |
0 |
0 |
0 |
109 |
| Horizontal Mergers and Product Quality |
0 |
0 |
0 |
33 |
0 |
0 |
2 |
130 |
| Horizontal Mergers and Product Quality- |
0 |
0 |
0 |
60 |
0 |
0 |
0 |
141 |
| Hospital Competition and Quality with Regulated Prices |
0 |
0 |
0 |
306 |
0 |
0 |
2 |
1,109 |
| Hospital Competition in the National Health Service: Evidence from a Patient Choice Reform |
0 |
0 |
0 |
70 |
0 |
0 |
2 |
141 |
| Hospital Competition in the National Health Service: Evidence from a Patient Choice Reform |
0 |
0 |
1 |
32 |
0 |
1 |
3 |
63 |
| Hospital Competition with Soft Budgets |
0 |
0 |
0 |
48 |
0 |
0 |
1 |
193 |
| Hospital Mergers with Regulated Prices |
0 |
0 |
0 |
90 |
1 |
2 |
4 |
142 |
| Hospital Mergers: A Spatial Competition Approach |
0 |
0 |
0 |
121 |
0 |
1 |
1 |
116 |
| Hospital Mergers: A Spatial Competition Approach |
0 |
0 |
0 |
37 |
0 |
0 |
2 |
127 |
| Hospital Reimbursement in an Oligopolistic Industry |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
1,042 |
| Hospital competition and quality with regulated prices |
0 |
0 |
0 |
149 |
0 |
1 |
3 |
387 |
| Hospital competition with soft budgets |
0 |
0 |
0 |
46 |
0 |
0 |
0 |
123 |
| Hospital competition with soft budgets |
0 |
0 |
0 |
31 |
0 |
0 |
1 |
62 |
| Hospital competition with soft budgets |
0 |
0 |
0 |
74 |
0 |
0 |
0 |
150 |
| How does the type of remuneration affect physician behaviour? Fixed salary versus fee-for-service |
0 |
0 |
2 |
72 |
1 |
2 |
4 |
144 |
| Margins and Market Shares: Pharmacy Incentives for Generic Substitution |
0 |
0 |
2 |
36 |
0 |
0 |
6 |
207 |
| Margins and Market Shares: Pharmacy Incentives for Generic Substitution |
0 |
0 |
0 |
114 |
0 |
0 |
1 |
122 |
| Margins and Market Shares:Pharmacy Incentives for Generic Substitution |
0 |
0 |
0 |
91 |
0 |
0 |
0 |
224 |
| Patents: Incentives for R&D or Marketing? |
0 |
0 |
0 |
9 |
0 |
0 |
2 |
51 |
| Patient Mobility, Health Care Quality and Welfare |
0 |
0 |
0 |
45 |
0 |
2 |
3 |
165 |
| Patient Mobility, Health Care Quality and Welfare |
0 |
0 |
1 |
51 |
0 |
0 |
3 |
152 |
| Patient Mobility, Health Care Quality and Welfare |
0 |
0 |
1 |
54 |
0 |
0 |
2 |
121 |
| Patient Mobility, Health Care Quality and Welfare |
0 |
0 |
0 |
42 |
0 |
0 |
2 |
122 |
| Patient mobility and health care quality when regions and patients differ in income |
0 |
0 |
1 |
14 |
1 |
1 |
3 |
68 |
| Paying for pharmaceuticals: uniform pricing versus two-part tariffs |
0 |
0 |
0 |
48 |
0 |
0 |
3 |
124 |
| Pharmaceutical Patents: Incentives for R&D or Marketing? |
0 |
0 |
0 |
275 |
0 |
0 |
3 |
1,091 |
| Price Regulation and Parallel Imports of Pharmaceuticals |
0 |
0 |
0 |
100 |
1 |
1 |
1 |
119 |
| Price Regulation and Parallel Imports of Pharmaceuticals |
0 |
0 |
0 |
13 |
0 |
2 |
5 |
119 |
| Price Regulation and Parallel Imports of Pharmaceuticals |
0 |
0 |
0 |
95 |
0 |
2 |
3 |
146 |
| Price and quality in spatial competition |
0 |
0 |
0 |
162 |
0 |
1 |
6 |
254 |
| Price and quality in spatial competition |
0 |
0 |
0 |
94 |
1 |
1 |
1 |
226 |
| Private Versus Public Health Care in a National Health Service |
0 |
0 |
1 |
1,282 |
1 |
1 |
9 |
6,001 |
| Public coverage of dental care: universal or targeted? |
0 |
1 |
8 |
8 |
0 |
3 |
9 |
9 |
| Public coverage of dental care: universal or targeted? |
0 |
0 |
0 |
0 |
1 |
3 |
7 |
7 |
| Public versus Private Health Care in a National Health Service |
0 |
0 |
0 |
1,228 |
0 |
0 |
1 |
6,640 |
| Quality and location choices under price regulation |
0 |
0 |
0 |
25 |
0 |
1 |
2 |
107 |
| Quality and location choices under price regulation |
0 |
0 |
0 |
21 |
0 |
1 |
2 |
109 |
| Quality competition with profit constraints: Do non-profit firms provide higher quality than for-profit firms? |
0 |
0 |
1 |
84 |
2 |
4 |
6 |
123 |
| Quality competition with profit constraints: Do non-profit firms provide higher quality than for-profit firms? |
0 |
0 |
0 |
44 |
0 |
0 |
1 |
146 |
| Quality competition with profit constraints: Do non-profit firms provide higher quality than for-profit firms? |
0 |
0 |
0 |
108 |
0 |
0 |
0 |
202 |
| Reference Pricing of Pharmaceuticals |
0 |
0 |
0 |
20 |
0 |
0 |
0 |
121 |
| Reference Pricing of Pharmaceuticals |
0 |
0 |
0 |
269 |
1 |
1 |
2 |
932 |
| Reference Pricing, Competition, and Pharmaceutical Expenditures: Theory and Evidence from a Natural Experiment |
0 |
0 |
8 |
111 |
0 |
1 |
13 |
398 |
| Reference pricing with endogenous generic entry |
0 |
0 |
0 |
52 |
0 |
0 |
0 |
90 |
| Reference pricing with endogenous generic entry |
0 |
0 |
0 |
16 |
0 |
0 |
1 |
76 |
| Regulation and Pricing of Pharmaceuticals: Reference Pricing or Price Cap Regulation? |
0 |
0 |
2 |
24 |
0 |
2 |
7 |
141 |
| Regulation and Pricing of Pharmaceuticals: Reference Pricing or Price Cap Regulation? |
0 |
0 |
0 |
308 |
0 |
0 |
1 |
1,344 |
| Regulation, generic competition and pharmaceutical prices: Theory and evidence from a natural experiment |
0 |
0 |
2 |
149 |
0 |
2 |
5 |
490 |
| Socioeconomic Status and PhysiciansíTreatment Decisions |
0 |
0 |
0 |
19 |
1 |
2 |
2 |
60 |
| Socioeconomic Status and Physicians’ Treatment Decisions |
0 |
0 |
0 |
10 |
1 |
2 |
3 |
72 |
| Taking the competitor´s pill: when combination therapies enter pharmaceutical markets |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
4 |
| Taking the competitor’s pill: when combination therapies enter pharmaceutical markets |
0 |
0 |
0 |
12 |
0 |
2 |
4 |
25 |
| The price of cost-effectiveness thresholds |
0 |
0 |
1 |
27 |
1 |
1 |
3 |
17 |
| The price of cost-effectiveness thresholds |
0 |
0 |
0 |
24 |
1 |
1 |
5 |
16 |
| Trade, renewable energy, and market power in power markets |
0 |
0 |
0 |
15 |
2 |
5 |
7 |
39 |
| Where are all the Physicans? Private vs. Public Health Care |
0 |
0 |
0 |
1 |
0 |
0 |
1 |
3,324 |
| Total Working Papers |
0 |
2 |
52 |
9,276 |
30 |
92 |
283 |
40,000 |
LogEc is hosted by the
Örebro University School of Business.